Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.73 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261465 | 0.89 | HRH3 (0.72) | HRH3RAB9AKDM4ENPC1PKM | |
| SCHEMBL6295832 | 0.85 | HRH3 (1.00) | HRH3DRD2DRD3 | |
| SCHEMBL5260036 | 0.85 | HRH3 (1.00) | HRH3DRD2DRD3 | |
| SCHEMBL5417574 | 0.82 | HRH3 (0.73) | HRH3RAB9AKDM4ENPC1PKM | |
| SCHEMBL5413880 | 0.82 | HRH3 (0.69) | HRH3RAB9AKDM4ENPC1PKM | |
| SCHEMBL6295835 | 0.80 | HRH3 (0.59) | HRH3RAB9AKDM4ENPC1PKM | |
| SCHEMBL5312656 | 0.80 | HRH3 (0.57) | HRH3RAB9AKDM4ENPC1PKM | |
| SCHEMBL14528958 | 0.76 | SMN1; SMN2 (0.54) | HRH3RAB9AKDM4ENPC1PKM | |
| SCHEMBL6292800 | 0.74 | HRH3 (1.00) | HRH3DRD2DRD3 | |
| SCHEMBL5261354 | 0.74 | HRH3 (1.00) | HRH3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268478-B1 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | ORTHO MCNEIL PHARM INC (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7199117-B2 | Phenyl-substituted imidazopyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7087757-B2 | Phenyl-substituted imidazopyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-7041827-B2 | Phenyl-substituted imidazopyridines | BREITENBUCHER J GUY | 2006-05-09 | — | — | US | disclosed |
| US-7041828-B2 | Phenyl-substituted imidazopyridines | BREITENBUCHER J GUY | 2006-05-09 | — | — | US | disclosed |
| US-6908929-B2 | Phenyl-substituted imidazopyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050090523-A1 | 2-(substituted phenyl)imidazo[1,2-a]pyridine compounds; use to treat disorders mediated by the histamine H3 receptor such as sleep disorders, attention deficit hyperactivity disorder, or Alzheimer's disease; 2-[4-[3-(Piperidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine for example | BREITENBUCHER J G (US) | 2005-04-28 | — | — | US | disclosed |
| US-20050085502-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J G (US) | 2005-04-21 | — | — | US | disclosed |
| US-20050085501-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J G (US) | 2005-04-21 | — | — | US | disclosed |
| US-20050049277-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J GUY (US) | 2005-03-03 | — | — | US | disclosed |
| US-20050043348-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J GUY (US) | 2005-02-24 | — | — | US | disclosed |
| EP-1268478-A2 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | Ortho McNeil Pharmaceutical, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020006934-A1 | Phenyl-substituted imidazopyridines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001074815-A2 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043348-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | HRH3 701/4885RAB9A 3610/4885KDM4E 1467/4885 |
| US-20050085502-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | HRH3 701/4885RAB9A 3610/4885KDM4E 1467/4885 |
| US-20050085501-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | HRH3 701/4885RAB9A 3610/4885KDM4E 1467/4885 |
| US-20050049277-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | HRH3 701/4885RAB9A 3610/4885KDM4E 1467/4885 |
| US-20050090523-A1 | 2-(substituted phenyl)imidazo[1,2-a]pyridine compounds; use to treat disorders mediated by the histamine H3 receptor such as sleep disorders, attention deficit hyperactivity disorder, or Alzheimer's disease; 2-[4-[3-(Piperidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine for example | HRH3, HRH4, HTR2C | HRH3 1/4885RAB9A 1937/4885KDM4E 225/4885 |
| US-20020006934-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | HRH3 701/4885RAB9A 3610/4885KDM4E 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.